Loading
A phase 2 trial of NK cell therapy in glioma & glioblastoma, run by Marzieh Ebrahimi, now recruiting.
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas is a phase 2 interventional study registered as NCT06687681 by Marzieh Ebrahimi, with 40 participants planned, started 2024-11-25 and due to reach its primary completion in 2025-11-25. Interventions recorded: NK cell therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/